Now on MedTalks

Dr. Tarantino sits down with Team Novo8™ member Tammy Davenport to put women with hemophilia in the spotlight. Tune in to hear them discuss the need for better comprehensive care and treatment options for female patients and how they're raising awareness.

Please see full Prescribing Information.

Individual results may vary.

US18NEGT00019
US18NEGT00019
Play
Pause
Skip
Volume
Chapters
Transcript
References
Subtitles
Fullscreen

Now on MedTalks

Chapters
Transcript
References

Dr. Tarantino sits down with Team Novo8™ member Tammy Davenport to put women with hemophilia in the spotlight. Tune in to hear them discuss the need for better comprehensive care and treatment options for female patients and how they're raising awareness.

Please see full Prescribing Information.

Individual results may vary.

Return to overview

Transcripts

Return to overview

References


Selected Important Safety Information

Do not use in patients who have had life-threatening hypersensitivity reactions, including anaphylaxis, to Novoeight® or its components, including hamster proteins.

Anaphylaxis and severe hypersensitivity reactions are possible. Patients may develop hypersensitivity to hamster proteins, which are present in trace amounts in the product. Should symptoms occur, discontinue Novoeight® and administer appropriate treatment.

Indications and Usage

Novoeight® (Antihemophilic Factor [Recombinant]) is indicated for use in adults and children with hemophilia A for control and prevention of bleeding, perioperative management, and routine prophylaxis to prevent or reduce the frequency of bleeding episodes.

Novoeight® is not indicated for the treatment of von Willebrand disease.

Important Safety Information

Do not use in patients who have had life-threatening hypersensitivity reactions, including anaphylaxis, to Novoeight® or its components, including hamster proteins.

Anaphylaxis and severe hypersensitivity reactions are possible. Patients may develop hypersensitivity to hamster proteins, which are present in trace amounts in the product. Should symptoms occur, discontinue Novoeight® and administer appropriate treatment.

Development of activity-neutralizing antibodies (inhibitors) may occur.  If expected plasma factor VIII activity levels are not attained, or if bleeding is not controlled with an appropriate dose, perform an assay that measures factor VIII inhibitor concentration.

The most frequently reported adverse reactions (≥0.5%) were injection site reactions, increased hepatic enzymes, and pyrexia.

Please click here for Prescribing Information.